|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2200060900 |
|
最近更新日期: Date of Last Refreshed on: |
2022-06-29 10:50:59 |
|
注册时间: Date of Registration: |
2022-06-14 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
鼻咽清毒颗粒防治鼻咽癌患者放疗所致鼻部、口腔急性放射性损伤的临床研究 |
|
Public title: |
Clinical study of Biyan Qingdu granule in preventing and treating acute radiation injury of nose and mouth caused by radiotherapy in patients with nasopharyngeal carcinoma |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
鼻咽清毒颗粒防治鼻咽癌患者放疗所致鼻部、口腔急性放射性损伤的临床研究 |
|
Scientific title: |
Clinical study of Biyan Qingdu granule in preventing and treating acute radiation injury of nose and mouth caused by radiotherapy in patients with nasopharyngeal carcinoma |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
ChiMCTR2200006121 |
|
申请注册联系人: |
林娟 |
研究负责人: |
王德勤 |
|
Applicant: |
LIN JUAN |
Study leader: |
WANG DEQING |
|
申请注册联系人电话: Applicant telephone: |
13751860617 |
研究负责人电话:
Study leader's |
13430372938 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1226976234@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
578045600@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省广州市白云区沙太北路389号 |
研究负责人通讯地址: |
广东省广州市白云区沙太北路389号 |
|
Applicant address: |
389 shatai North Road, Baiyun District, Guangzhou, Guangdong |
Study leader's address: |
389 shatai North Road, Baiyun District, Guangzhou, Guangdong |
|
申请注册联系人邮政编码: Applicant postcode: |
510080 |
研究负责人邮政编码: Study leader's postcode: |
510080 |
|
申请人所在单位: |
广州白云山和记黄埔中药有限公司 |
||
|
Applicant's institution: |
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co., Ltd. |
||
|
研究负责人所在单位: |
广州白云山和记黄埔中药有限公司 |
||
|
Affiliation of the Leader: |
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co., Ltd. |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
21/481-3152 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
国家癌症中心/中国医学科学院北京协和医学院肿瘤医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-12-09 00:00:00 | ||
|
伦理委员会联系人: |
徐震纲 |
||
|
Contact Name of the ethic committee: |
Zhengang Xu |
||
|
伦理委员会联系地址: |
北京市朝阳区潘家园南里17号 |
||
|
Contact Address of the ethic committee: |
No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, P.R. China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
中国医学科学院肿瘤医院 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Cancer Hospital Chinese Academy of Medical Science |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市朝阳区潘家园南里17号 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, P.R. China |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
申办方自筹 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
Self raised by the sponsor |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
鼻咽癌放化疗并发症 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Complications of radiotherapy and chemotherapy for nasopharyngeal carcinoma |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
主要目的:评估鼻咽清毒颗粒用于防治鼻咽癌患者放疗所致鼻腔分泌物增多、口腔粘膜损伤的有效性。次要目的:评估鼻咽清毒颗粒用于防治鼻咽癌患者放疗所致鼻粘膜充血、咽痛、咽干灼热、鼻部并发症的有效性与安全性。 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
Objective: To evaluate the efficacy of Biyan Qingdu granule in preventing and treating the increase of nasal secretion and oral mucosal injury caused by radiotherapy in patients with nasopharyngeal carcinoma. Secondary objective: To evaluate the efficacy and safety of Biyan Qingdu granule in the prevention and treatment of nasal mucosal congestion, sore throat, dry throat burning and nasal complications caused by radiotherapy in patients with nasopharyngeal carcinoma. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
试验药物鼻咽清毒颗粒是由广州白云山和记黄埔中药有限公司研制的已上市中成药,批准文号:国药准字Z44022139,本品成分为:野菊花、苍耳子、重楼、茅莓根、两面针、夏枯草、龙胆、党参。对照组采取基础治疗(生理盐水冲洗鼻腔,每日1-2次),试验组采用基础治疗并鼻咽清毒颗粒(一次20g,每日2次),两组采取基础治疗相同。 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
The test drug Biyan Qingdu granule is a listed Chinese patent medicine developed by Guangzhou Baiyun Mountain Hutchison Huangpu traditional Chinese Medicine Co., Ltd. with approval number of Guoyao Zhunzi z44022139. The ingredients of this product are: wild chrysanthemum, Xanthium sibiricum, Paris polyphylla, Rubus root, Nitraria, Prunella vulgaris, gentian and Codonopsis pilosula. The control group was treated with basic treatment (flushing the nasal cavity with normal saline, 1-2 times a day), and the experimental group was treated with basic treatment and Biyan Qingdu granule (20g once, twice a day). The two groups were treated with the same basic treatment. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
(1)年龄≥18周岁; |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
(1) Age ≥ 18 years old; |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
(1)合并心脑血管、肺、肾和造血系统严重原发性疾病。 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
(1) Combined with serious primary diseases of cardio cerebrovascular, lung, kidney and hematopoietic system. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-04-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-07-22 00:00:00 至 To 2025-07-21 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
通过随机系统产生随机号码 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A random number is generated by a random system |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
暂未确定 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Not determined yet |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表,将所得的试验数据收集并输入进电子数据库。EDC系统由CRO方提供。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case record form, collect and input the obtained test data into the electronic database. EDC system is provided by cro. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |